Volume 143, Issue 2, Pages (November 2016)

Slides:



Advertisements
Similar presentations
2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
Advertisements

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.
Volume 146, Issue 2, Pages (August 2017)
Comparison of continuous non-invasive finger arterial pressure monitoring with conventional intermittent automated arm arterial pressure measurement in.
A Source for Feature-Based Attention in the Prefrontal Cortex
Back to the Future: Introduction and Conclusions
Strong Evidence That KIAA0319 on Chromosome 6p Is a Susceptibility Gene for Developmental Dyslexia  Natalie Cope, Denise Harold, Gary Hill, Valentina.
Volume 150, Issue 1, Pages (July 2018)
The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: A systematic review and indirect comparison  Marrissa.
Are patients willing to travel for better ovarian cancer care?
L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L
Volume 148, Issue 1, Pages (January 2018)
Volume 146, Issue 3, Pages (September 2017)
A. Melamed, E. J. Diver, A. A. Gockley, E. M. Hinchcliff, L
Volume 151, Issue 1, Pages (October 2018)
What Palliative Care-Related Problems Do Patients Experience at HIV Diagnosis? A Systematic Review of the Evidence  Victoria M. Simms, MSc, Irene J. Higginson,
Volume 145, Issue 2, Pages (May 2017)
Volume 138, Issue 1, Pages (July 2015)
Vulvar intraepithelial neoplasia: Risk factors for recurrence
Corrigendum to “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer” [Gynecologic Oncology 110: 13–21, 2008]  Douglas.
M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns
Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei 
The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 
Reporting of method comparison studies: a review of advice, an assessment of current practice, and specific suggestions for future reports  A. Abu-Arafeh,
Volume 136, Issue 2, Pages (February 2015)
Supportive care plans: Linking patient-reported outcomes to evidence-based supportive care across the cancer continuum  E.E. Stevens, J.N. Bottsford-Miller,
Volume 148, Issue 1, Pages (January 2018)
Jojanneke M. Seinen, Maarten G
Volume 142, Issue 3, Pages (September 2016)
National trends in management of stage IIIC1 and IIIC2 uterine cancer: Chemotherapy and radiotherapy in isolation and sequence  J. Chino, J.R. Foote,
Volume 152, Issue 1, Pages (January 2019)
K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani
Volume 152, Issue 1, Pages (January 2019)
Volume 143, Issue 2, Pages (November 2016)
Laparoscopic staging for stage I epithelial ovarian cancer: Analysis of the National Cancer Data Base  A. Melamed, J.T. Clemmer, N.L. Keating, J.D. Wright,
The origins of multidisciplinary cancer care
Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN)
Comparing the health and economic impacts of cervical cancer screening strategies using the Cancer Risk Management Model (CRMM)  C. Popadiuk, A.J. Coldman,
I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M
Survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum  A. Ellis, M.K. Frey, L.M. Koontz, S. Shyne,
Volume 152, Issue 1, Pages (January 2019)
Volume 13, Issue 5, Pages (September 2013)
Volume 150, Issue 1, Pages (July 2018)
Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates  N.A. Latif, E.M. Ko,
Volume 152, Issue 1, Pages (January 2019)
Interventions to Promote Long-Term Participation in Physical Activity After Stroke: A Systematic Review of the Literature  Jacqui H. Morris, PhD, Stephen.
HPV vaccines – A review of the first decade
Volume 147, Issue 1, Pages (October 2017)
Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.
Sarah Clark, Pauline J. Reeves  Radiography 
Volume 152, Issue 1, Pages (January 2019)
The complex interaction of cancer surgery, complications, and patient-reported outcomes: A single score is not enough  K.M. Doll, E.L. Barber, J.T. Bensen,
Volume 142, Issue 2, Pages (August 2016)
Annika Idahl, Andrea Hermansson, Ann Lalos  Gynecologic Oncology 
Volume 152, Issue 1, Pages (January 2019)
Volume 152, Issue 1, Pages (January 2019)
Volume 130, Issue 3, Pages (September 2013)
Volume 130, Issue 1, Pages (July 2013)
Volume 152, Issue 1, Pages (January 2019)
Volume 152, Issue 1, Pages (January 2019)
Volume 147, Issue 3, Pages (December 2017)
High-risk cancer, unequal care: Disparities in the complete surgical staging of high- grade endometrial cancer in the Southeastern United States  J.R.
Should ovarian preservation be considered for women younger than 60 years with endometrial carcinoma?  L.M. Bean, K. Taylor, K.M. Anderson, M.A. Davis,
Clinical and Translational Radiation Oncology
C.M. Chalmers, A.M. Bal  British Journal of Anaesthesia 
Volume 115, Issue 1, Pages (October 2009)
Mark I. Block, MD  The Annals of Thoracic Surgery 
Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD 
Systematic review of methodology used in clinical studies evaluating the benefits of proton beam therapy  Mercy Ofuya, Lucy McParland, Louise Murray,
Volume 3, Issue 5, Pages (November 2017)
Presentation transcript:

Volume 143, Issue 2, Pages 287-293 (November 2016) Working together to shape the endometrial cancer research agenda: The top ten unanswered research questions  Y. Louise Wan, Rachel Beverley-Stevenson, Daloni Carlisle, Sinead Clarke, Richard J. Edmondson, Steve Glover, Julie Holland, Carol Hughes, Henry C. Kitchener, Sarah Kitson, Tracie Miles, Richard Morley, Jo Morrison, Linsey Nelson, Melanie Powell, Laura Sadler, Anne Tomlinson, Katharine Tylko-Hill, Jo Whitcombe, Emma J. Crosbie  Gynecologic Oncology  Volume 143, Issue 2, Pages 287-293 (November 2016) DOI: 10.1016/j.ygyno.2016.08.333 Copyright © 2016 The Authors Terms and Conditions

Fig. 1 Study flow diagram showing the number of participants and submissions at each stage. Gynecologic Oncology 2016 143, 287-293DOI: (10.1016/j.ygyno.2016.08.333) Copyright © 2016 The Authors Terms and Conditions

Fig. 2 Comparison of thematic analysis between responses from (A) lay and (B) professional participants. The submissions from the 413 respondents to the initial survey were thematically analysed. Where respondents had offered multiple suggestions these were analysed separately. Gynecologic Oncology 2016 143, 287-293DOI: (10.1016/j.ygyno.2016.08.333) Copyright © 2016 The Authors Terms and Conditions

Fig. 3 Distribution of evidence base for questions from each of 7 domains. Each of 247 unique questions was searched against current literature. The frequency with which questions from each domain were submitted and the proportion within each of these which had been addressed at each level of evidence (Level 1–5 - Oxford 2011 Levels of Evidence [17]) are shown. Those research questions where level 1 evidence was available were further subclassified into those where the conclusion showed that there was sufficient evidence i.e. ‘answered’ and those where the evidence was insufficient (i.e. level 1 alone) to state that further research was required. Gynecologic Oncology 2016 143, 287-293DOI: (10.1016/j.ygyno.2016.08.333) Copyright © 2016 The Authors Terms and Conditions

Fig. 4 Frequency of prioritisation of the top 30 questions in prioritisation survey according to background. The frequency with which each of the 30 questions was prioritised by participants as their top 2 most important in each domain is shown along with the relative proportion of each stakeholder group which made this selection. The responses of groups making up the lay participants are shown in shades of green whilst the responses from groups making up the professional participants are shaded blue. Those questions selected to constitute the final ten are indicated by the asterisks. Gynecologic Oncology 2016 143, 287-293DOI: (10.1016/j.ygyno.2016.08.333) Copyright © 2016 The Authors Terms and Conditions

Fig. 5 Final top ten unanswered research questions in EC. Gynecologic Oncology 2016 143, 287-293DOI: (10.1016/j.ygyno.2016.08.333) Copyright © 2016 The Authors Terms and Conditions